KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gains from Sales and Divestitures (2016 - 2018)

Biomarin Pharmaceutical (BMRN) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $963062.0 as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Gains from Sales and Divestitures rose 14.93% year-over-year to $963062.0, compared with a TTM value of $963062.0 through Dec 2018, up 14.93%, and an annual FY2018 reading of $963062.0, up 14.93% over the prior year.
  • Gains from Sales and Divestitures was $963062.0 for Q4 2018 at Biomarin Pharmaceutical, up from $837926.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $963062.0 in Q4 2018 and bottomed at $383332.0 in Q4 2014.
  • Average Gains from Sales and Divestitures over 5 years is $684964.8, with a median of $751203.0 recorded in 2016.
  • The sharpest move saw Gains from Sales and Divestitures skyrocketed 53.53% in 2016, then grew 11.54% in 2017.
  • Year by year, Gains from Sales and Divestitures stood at $383332.0 in 2014, then increased by 27.64% to $489301.0 in 2015, then surged by 53.53% to $751203.0 in 2016, then increased by 11.54% to $837926.0 in 2017, then grew by 14.93% to $963062.0 in 2018.
  • Business Quant data shows Gains from Sales and Divestitures for BMRN at $963062.0 in Q4 2018, $837926.0 in Q4 2017, and $751203.0 in Q4 2016.